Relmada Therapeutics (RLMD) Scheduled to Post Earnings on Wednesday

Relmada Therapeutics (NASDAQ:RLMD) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Relmada Therapeutics (NASDAQ:RLMD) last announced its earnings results on Wednesday, May 8th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.18. On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relmada Therapeutics Stock Down 2.4 %

Shares of RLMD traded down $0.08 during mid-day trading on Tuesday, reaching $3.31. 25,959 shares of the stock traded hands, compared to its average volume of 177,597. The stock has a fifty day simple moving average of $3.38 and a 200 day simple moving average of $4.18. Relmada Therapeutics has a 12-month low of $2.41 and a 12-month high of $7.22. The firm has a market cap of $99.86 million, a price-to-earnings ratio of -1.05 and a beta of 0.50.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group downgraded Relmada Therapeutics from a “neutral” rating to a “sell” rating and lowered their target price for the company from $3.00 to $2.00 in a research note on Wednesday, June 5th.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.